CORT

Corcept Therapeutics is a commercial-stage company focused on discovering and developing small molecule medications that modulate cortisol activity to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders including Cushing's syndrome, metabolic dysfunction-associated steatohepatitis (MASH), and amyotrophic lateral sclerosis (ALS). The company markets Korlym (mifepristone) 300 mg tablets and an authorized generic version for treating hypercortisolism in the United States, with ongoing research into how cortisol modulation may improve outcomes in fatty liver disease, MASH, and ALS.

Pipeline

Catalyst Calendar